Clinical Trial

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

Study acronym: TOKIN
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-11-10; most recent amendment 2026-04-28.
Status change: Recruiting → Active, Not Recruiting 2026-04-28
Status change: Not Yet Recruiting → Recruiting 2021-01-08
Trial Details
NCT Number NCT04626024
Lead Sponsor Baylor College of Medicine
Conditions Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission
Enrollment 17 participants
Start Date 2020-12-22
Primary Completion 2028-11-15 (estimated)
Study Completion 2028-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-04